Management of oropharyngeal candidiasis with localized oral miconazole therapy: Efficacy, safety, and patient acceptability

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 369-374

  Collins, Curtis D ^a   Cookinham, Sarah ^a   Smith, Jeannina ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antifungal agents; Esophageal candidiasis; Miconazole

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; LAURIAD; LORAMYC; MICONAZOLE; PLACEBO; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; BLEEDING; BURNING SENSATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; HEADACHE; HUMAN; MOUTH DISCOMFORT; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SINGLE DRUG DOSE; TASTE DISORDER; TREATMENT OUTCOME; VOMITING;

EID: 84861305377     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S14047     Document Type: Review

References (28)

1. Pankhurst CL. Candidiasis (oropharyngeal). Clin Evid (Online). 2009;2009:1304. Epub 2009 Mar 18.
2. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: a review. Part 3. Treatment of oral candidosis. Aust Dent J. 1998;43(4):244-249.
3. Ellepola ANB, Samaranayake LP. Antimycotic agents in oral candidosis: an overview: 1. Clinical variants. Dent Update. 2000;27(3): 111-112,114-116.
4. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol. 1992;73(2):171-180.
5. Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010;18(8):985-992.
6. Center for Drug Evaluation and Research, US Food and Drug Administration (FDA). Summary Review: application 22404Orig1s000; NDA22-404, Oravig (miconazole) for oropharyngeal candidiasis. US Center for Drug Evaluation and Research; 2010. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2010/022404Orig1s000SumR. pdf. Accessed May 12, 2011.
7. Oravig [prescribing information]. Woodcliff Lake, NJ: Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc; 2010. Available at: www.oravig.com/oral-thrush-once-daily/hcp-faqs.html. Accessed May 12, 2011.
8. Manfredi M, McCullough MJ, Polonelli L, et al. In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus. Oral Microbiol Immunol. 2006;21(3):177-182.
9. Luz Paniagua GC, Monroy EP, Negrete EA, Vaca SP. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients. Rev Latinoam Microbiol. 2002;44(2):65-68.
10. Hernáez ML, Gil C, Pla J, Nombela C. Induced expression of Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast. 1998;14(6):517-526.
11. Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses. 2010;53(5):434-437.
12. Ghannoum MA, Herbert J, Isham N. Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance. Mycoses. 2010 Mar 4. [Epub ahead of print]
13. Cardot JM, Chaumont C, Dubray C, Constantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharmacol. 2004;58(4): 345-351.
14. Chaumont C, Cardot JM, Dubray C, Constantini D, Aiache JM. Safety, acceptability, and adhesion of novel bioadhesive slow release tablet of miconazole in a phase I study. Journal de mycologie médicale. 2003; 13:13-18.
15. Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira I. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr. 2004;35(2): 144-150.
16. Bensadoun RJ, Daoud J, El Gueddari B, et al. Comparison of the efficacy and safety of miconazole 50 mg mucoadhesive buccal tablets with miconazole 500 mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112(1):204-211.
17. Vazquez JA, Patton LL, Joel B, et al. Randomized, comparative, doubleblind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES). HIV clinical trials. 2010;11(4):186-196.
18. Hamza OJ, Matee MI, Bruggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIVinfected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis. 2008;47(10):1270-1276.
19. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42(8):1179-1186.
20. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44(4): 607-614.
21. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5): 503-535.
22. Villanueva, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001; 33(9):1529-1535.
23. Smith JA. Is there a role for therapeutic drug monitoring of antifungal agents? Curr Infect Dis Rep. 2009;11(6):439-446.
24. Klotz SA. Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis. 2006;42(8):1187-1188.
25. Who Technical Report Series, No. 920. The selection and use of essential medicines. Available at: http://apps.who.int/medicinedocs/en/d/Js 4881e/4.1.5.html#Js4881e.4.1.5. Accessed April 11, 2011.
26. Sharon V, Fazel N. Oral candidiasis and angular cheilitis. Dermatol Ther. 2010;23(3):230-242.
27. Miconazole (Oravig) for oropharyngeal candidiasis. Med Lett Drugs Ther. 2010;29;52(1352):95-96.
28. 2010 Redbook. Montvale, NJ: Thomson Healthcare; 2010.